Shilpa Gupta: I was honored to present PROs from the pivotal EV-302 trial at ASCO24
Shilpa Gupta shared a post on LinkedIn:
“On behalf of the entire EV 302 team, I was honored to present at American Society of Clinical Oncology (ASCO) mtg,
the Patient Reported Outcomes (PROs)from the pivotal EV-302 trial of 1L EV-pembro vs platinum chemotherapy in advanced urothelial cancer.
Patient voices are very critical besides efficacy and safety of treatment regimens.
The novelty of this study was that patients filled out surveys not just during treatment but also beyond progression and through survival follow up, for which we are eternally grateful.
Overall, EV pembro doubled the PFS and OS compared to chemotherapy without a detriment to their quality of life, pain or global health status. In particular, patients with moderate to severe pain at baseline saw a clinically meaningful improvement in their symptoms.
This study provides important information for designing future trials. ”
Source: Shilpa Gupta/LinkedIn
Dr. Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023